Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brexit: UK Gov’t Says Retaining The EMA Cannot Be A “Line In The Sand” Matter

Executive Summary

The European Medicines Agency is important to the UK but the government cannot say it will be a non-negotiable point in future talks regarding the country’s departure from the EU.

You may also be interested in...

Brexit: EMA Has A Visit A Week From Potential Hosts

At least half a dozen countries are interested in hosting the European Medicines Agency if Brexit means it has to leave London. But do they have what it would take?

UK MPs On Brexit: EMA And MHRA Are ‘Completely Intermingled’

Perhaps appealing to the wider European audience, UK legislators debating Brexit’s impact warn of damage to EU and as well as UK regulatory systems.

‘Standardized’ Comment From Brexit Minister Raises Hopes For Parallel EU/UK Drug Approval System

The way in which pharmaceuticals might be regulated in the UK after the country leaves the EU is a big unknown. As MPs get to have their say on the matter, the Pink Sheet tries to gauge government thinking.

Related Content


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts